New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026

DUBLIN and BRIDGEWATER, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced upcoming presentations at the European Society of Cardiology (ESC) Congress 2026, August 28(t)(h )- 31(st), in Munich, Germany.

The accepted abstracts add to the body of evidence generated from REDUCE-IT and related research investigating cardiovascular risk factors, biomarkers and potential mechanisms associated with the effects of icosapent ethyl or eicosapentaenoic acid (EPA). The presentations include analyses of treatment adherence, long-term outcomes, lipoprotein(a) [Lp(a)], coagulation biomarkers and cellular pathways relevant to cardiovascular disease.